NASDAQ: KLRAKailera Therapeutics Inc Stock
$16.23+0.49 (+3.11%)
Updated Sep 4, 2026
KLRA Price
$16.23
Fair Value Price
$1.27
Market Cap
$2.10B
52 Week Low
$15.15
52 Week High
$28.23
P/E
N/A
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
N/A
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KLRA Overview
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KLRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KLRA
Ranked#325 of 458
Ranked#325 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.55 | A | |
| $111.62 | A | |
| $7.10 | A |
Be the first to know about important KLRA news, forecast changes, insider trades & much more!
KLRA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KLRA ($16.23) is overvalued by 1,180.35% relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KLRA ($16.23) is not significantly undervalued (1,180.35%) relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KLRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more KLRA due diligence checks available for Premium users.
Valuation
KLRA fair value
Fair Value of KLRA stock based on Discounted Cash Flow (DCF)
Price
$16.23
Fair Value
$1.27
Overvalued by
1,180.35%
KLRA ($16.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KLRA ($16.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KLRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
5.56x
KLRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KLRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$111.3M
Profit Margin
0%
Assets to liabilities
Assets
$1.2B
Liabilities
$93.0M
Debt to equity
0.08
KLRA's short-term assets ($929.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLRA's short-term assets ($929.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$77.5M
Investing
-$571.0M
Financing
$667.0M
KLRA vs Biotech Stocks
Kailera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.